Treatment of epidermal growth factor receptor antagonist-induced skin rash

• Verfasst von: Hassel, Jessica C. [VerfasserIn]
• Verfasst von: Kripp, Melanie [VerfasserIn]
• Verfasst von: Batran, Salah-Eddin al- [VerfasserIn]
• Verfasst von: Hofheinz, Ralf-Dieter [VerfasserIn]
• Titel: Treatment of epidermal growth factor receptor antagonist-induced skin rash
• Titelzusatz: results of a survey among German oncologists
• Verf.angabe: Jessica C. Hassel, Melanie Kripp, Salah Al-Batran, Ralf-Dieter Hofheinz
• E-Jahr: 2010
• Jahr: [March 2010]
• Umfang: 5 S.
• Fussnoten: Gesehen am 27.03.2023
• Titel Quelle: Enthalten in: Onkologie
• Ort Quelle: Basel : Karger, 1978
• Jahr Quelle: 2010
• Band/Heft Quelle: 33(2010), 3 vom: März, Seite 94-98
• ISSN Quelle: 1423-0240
• DOI: doi:10.1159/000277656
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1840195444

Abstract

Background: Skin toxicities are frequent in patients receiving epidermal growth factor receptor (EGFR) antagonists. Grading and management of these skin reactions are poorly standardized. Materials and Methods:</i> We conducted a survey among German oncologists using a 7-item questionnaire distributed by e-mail via the working groups Internistische Onkologie (AIO) and Dermatologische Onkologie (ADO). The oncologists were provided with pictures and history of a patient with an acneiform rash and were asked to provide information on grading and treatment strategies. Results: 106 medical oncologists and 43 dermatooncologists responded to the survey. The scoring of the skin rash was indicated as follows (National Cancer Institute common toxicity criteria (NCICTC) grades 1/2/3;%): 10/59/31. 22% of the polled medical oncologists use preemptive treatment of skin rash. In the presented case, 91% chose local treatment with mainly hydrocortisone or antibiotic cream, and 64% chose systemic treatment with an antibiotic or isotretinoin. Only 9% of the medical oncologists would have referred the patient to a dermatologist. Dermatooncologists used more local antibiotics (p = 0.006) and rather less local steroids (p = 0.199). With regard to systemic treatment, dermatooncologists more often used isotretinoin (p = 0.002). In addition, dermatooncologists less often delayed cetuximab treatment because of skin toxicity (p = 0.009). Conclusions: The results of the present analysis illustrate that grading and treatment of EGFR antagonistinduced skin toxicities are very heterogeneous. Clearly, more randomized trials and a simple and reliable grading system are warranted.